Cereno Scientific
BiotechnologyView the employees at
Cereno Scientific-
Emmy A. Clinical Trial Manager at Cereno Scientific
-
United States
-
Rising Star
Nora A Senior Clinical Research Associate at Cereno Scientific-
Houston, Texas, United States
-
Rising Star
John O Study Manager at Cereno-
Top 10%
Fredrik Frick, PhD Head of Clinical Operations, Cereno Scientific-
Gothenburg, Vastra Gotaland County, Sweden
-
Rising Star
Overview
Cereno Scientific is a clinical stage biotech company within cardiovascular diseases. The lead drug candidate, CS1, is a Phase II candidate in development for the treatment of the rare disease pulmonary arterial hypertension (PAH) and thrombotic indications. CS1 is an HDAC (Histone DeACetylase) inhibitor that acts as an epigenetic modulator with anti-thrombotic, anti-inflammatory, anti-fibrotic and pressure-relieving properties, all relevant for PAH. In addition, Cereno has two promising preclinical development programs targeted at treating cardiovascular diseases. The company is headquartered in AstraZeneca’s BioVenture Hub, Sweden, and has a US subsidiary Cereno Scientific Inc. based in Kendall Square in Boston, Massachusetts, US. Cereno is listed on the Swedish Spotlight Stock Market (CRNO B). More information on www.cerenoscientific.com.
-